Weight-loss jabs for children ‘are effective and help prevent mealtime battles'
Experts at the European Congress on Obesity in Malaga, Spain, presented findings showing the drugs helped severely obese youngsters shed pounds on top of the diet and lifestyle plan they were already following.
Weight-loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings and are available on the NHS for adults with a high body mass index (BMI), or via private providers.
The National Institute for Health and Care Excellence (Nice) stopped its appraisal of semaglutide (Wegovy) for managing obesity in children aged 12 to 17 after the manufacturer, Novo Nordisk, said it was unable to provide an evidence submission.
However, specialist paediatric clinics can prescribe weight-loss injections if there is a proven clinical need.
Side-effects of weight-loss drugs include nausea, diarrhoea, stomach cramps and vision problems.
Dr Annika Janson, from Karolinska University Hospital in Sweden – who presented the new research, said: 'GLP-1 drugs are increasingly used to treat obesity in adults.
'They can also be used in children from the age of 12 and clinical trials have shown children lose 5%-16% of their body weight after a year of treatment.
'However, treating children in real-life situations has challenges that don't come up in research studies.
'Children have varying degrees of obesity, co-morbidities and complications and may have faced problems in supply of the drug, financing it or taking it.
'As a consequence, it is difficult to isolate the effect of adding GLP-1 drugs to the plethora of treatments that are already available.'
To address this question, Dr Janson and colleagues added GLP-1 receptor agonists to an existing treatment programme for child obesity.
The study involved 1,126 children (52% of them boys) aged up to 16 with severe obesity who were receiving intensive health behaviour and lifestyle treatment (IHBLT) at the National Childhood Obesity Centre in Stockholm.
IHBLT involves working with children, families and schools and looks at healthy foods, meal size, meal order, screen time, exercise and psychological wellbeing.
From 2023, GLP-1 drug liraglutide was included for around one in four patients. Later on, the drug semaglutide (Wegovy) was used.
While the reduction in BMI was similar between the groups until 2022, adding a weight loss jab had an additional effect.
Some 30% on liraglutide dropped enough weight to improve their health, compared with around 27% of those treated earlier on with no jab.
While the differences do not seem big, and not all children were taking the drug at all points, it suggests a trend, Dr Janson said. She said there were better later results with semaglutide.
'Only a fraction of the children had GLP-1 drugs and most of those who did started on them six to 12 months into the treatment programme. Longer-term treatment may lead to greater improvements in BMI,' she said.
'These are just early indications but it does look as if the average effect of being a patient at our clinic has improved after adding GLP-1 drugs to the toolbox.'
She added: 'Many children with severe obesity describe hunger and a strong appetite – both of which GLP-1 receptor agonists are known to help with.
'Results beyond obesity are also important. The families reported reduced conflicts around food and improved capacity for other lifestyle adaptations.
'It was easier to stick to meals and limit snacks. Portions could be down-sized. For some children, not being hungry all the time is a new feeling.
'GLP-1 receptor agonists are clearly beneficial to many children with severe obesity and, while they won't help in all cases, more children should have access to these important medications.'
A spokesman for Novo Nordisk said: 'Novo Nordisk did not submit evidence for a Nice appraisal for semaglutide and liraglutide for managing overweight and obesity in young people aged 12 to 17 years due to a lack of utility data and risk equations in linking weight loss in adolescents to long-term outcomes.
'As such, there are significant limitations in estimating the cost-effectiveness in this patient population, utility estimates that adequately capture the full impact on their quality of life, and not enough data to support an economic model that meets the Nice reference case.
'At this time, Novo Nordisk does not intend to make an evidence submission for the appraisal of semaglutide and liraglutide for managing overweight and obesity in young people aged 12 to 17 for the use in the NHS.
'We will continue to evaluate our evidence package in consideration of supporting any potential future submission for this patient group.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
20 minutes ago
- Daily Mirror
Love Island star urges fans to get a key health check
The NHS also claims that such health examinations save 'thousands of lives every year' Cara De La Hoyde-Massey has encouraged fans to prioritise an essential health check-up, even if it seems daunting. The former Love Island star, 34, issued the message in a conversation with celebrity stylist Bronagh Meere on The School Runway Podcast. "Oh, I had a smear this week as well," Cara told her fellow co-host. "...Everyone should get their smears, guys, just a little PSA [public service announcement]. Get your smear, don't be scared, just do it." Joining the conversation, Bronagh said: "Yeah, 100%. I mean, I get that some people'll get nervous." Cara said there was no need to worry. She acknowledged it wasn't exactly comfortable. However, she then made light of the situation. She said, speaking candidly: "Me and the nurse were laughing because I was like, 'Oh, it goes up there a lot easier now.' Obviously, once two [kids] have come out, it just flies up there, you ain't got nothing to worry about." Cara isn't alone in highlighting the necessity of smear tests. The NHS also frequently stresses that smear tests save 'thousands of lives' per year. The health service routinely invites eligible Brits aged 25 to 64 for cervical screenings every few years. READ MORE: 'I flew to Ibiza for a night out and it was cheaper than staying in the UK' READ MORE: Common Sunday Dinner herb fights dementia, diabetes, heart disease and eczema These five-minute examinations require a patient to undress from the waist down and recline on a bed. A nurse will then carefully place a tube-shaped speculum into the vagina and open it to view the cervix, being the neck of the uterus. A soft brush will collect cell samples from the cervix. Smear tests are particularly key for observing different types of 'human papillomavirus (HPV)', a prevalent collection of viruses that carry the risk of causing cervical alterations. HPV can spread through multiple ways, including through sexual intercourse, direct skin-to-skin genital contact, and the sharing of sexual toys. While the body eliminates many strains of HPV, some can linger for extended periods. These high-risk strains can lead to health problems like genital warts or, in more serious cases, cervical cancer. "Cervical screening checks the health of your cervix and helps find any abnormal changes before they can turn into cancer," NHS guidance explains. "It's not a test for cancer, it's a test to help prevent cancer. Cervical screening checks a sample of cells from your cervix for certain types of human papillomavirus (HPV). These types of HPV can cause abnormal changes to the cells in your cervix and are called 'high-risk' types of HPV. "If high-risk types of HPV are found during screening, the sample of cells is also checked for abnormal cell changes. If abnormal cells are found, they can be treated so they do not get a chance to turn into cervical cancer." Cervical screening invitations are typically mailed, allowing appointments to be arranged upon receipt. People aged 25 to 49 receive invitations for screenings every three years, whereas those aged 50 to 64 are invited every five years. Anyone over 65 is asked only if their recent test was abnormal. "If you missed your last cervical screening, you do not need to wait for a letter to book an appointment," the NHS adds. Am I at risk of cervical cancer? The NHS warns that anyone with a cervix could be at risk of cervical cancer if they have experienced 'any kind of sexual contact'. This encompasses: Vaginal, oral or anal sex Any skin-to-skin contact with the genital area Sharing sex toys It is also relevant in these situations: You are a trans man with a cervix You have received the HPV vaccine You have undergone a partial hysterectomy that did not remove all of your cervix You have only ever had one sexual partner, or you've had the same partner for a long time You are lesbian or bisexual
Scottish Sun
27 minutes ago
- Scottish Sun
New fat jabs warning over ‘increased risk of cancer – as experts fear they ‘stop common medication working'
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WEIGHT loss jabs could prevent a medication taken by millions of women from working - and increase patients' risk of cancer. The British Menopause Society said the jabs could cause hormone imbalance in women taking hormone replacement therapy (HRT), particularly for those with obesity, putting them 'at increased risk of womb cancer'. 1 Women commonly take a progesterone pill along with oestrogen patches or cream Credit: Getty It follows warnings to women on weight loss medications to take effective contraception, as the jabs could render the pill less effective. That's because weight loss drugs Wegovy and Mounjaro - as well as diabetes jab Ozempic - can delay the absorption of pills taken orally, as well slowing down the passage of food through the gut. Guidance suggests women taking HRT in pill form may also be at risk. The British Menopause Society (BMS) told doctors to closely monitor menopausal women on HRT who are also using weight-loss jabs. The treatment tops up the hormones oestrogen and progesterone, which dip to low levels as the menopause approaches. Data from 2023-24 showed that 2.6 million women in England rely on the drugs to alleviate hot flushes, night sweats, difficulty sleeping and mood changes. "During the last two years, since semaglutide and tirzepatide [the active ingredients in Wegovy and Mounjaro] received licenses for weight loss, there has been an increase in uptake of these medications through private clinics, while NHS prescribing is limited to specialist weight management services," the BMS guidance stated. "There are no current data available about numbers of women receiving HRT concurrently with semaglutide or tirzepatide." The most common form of HRT is a progesterone pill alongside a skin patch or gel to deliver oestrogen, but some people opt for a combined pill. Progesterone balances out the effects of oestrogen, which on its own stimulates the growth of the womb lining, and can cause 'abnormal cells and cancer' to grow. Women taking fat jabs need 'effective contraception' - as health chiefs warn of serious harm to unborn babies The menopause experts expressed concern over the loss of the progesterone's protective effect on the womb as a result of weight loss jabs. They recommended that doctors move women taking progesterone orally to an intrauterine device, such as a Mirena coil, or increase their dose of progesterone. Prof Annice Mukherjee, a consultant endocrinologist and member of the society's medical advisory council, who led on the guidance, told The Telegraph that a hormone imbalance could put women 'at increased risk of womb cancer' - particularly if they are obese. 'Oestrogen is almost always given through the skin for HRT in women living with obesity, but progesterone is frequently given as a tablet, and that formulation is thought to be the safest route for women who have complicated health issues,' she said. 'If we then start one of these injectable weight-loss drugs, then you're preferentially stopping absorption of the progestogen that's coming in orally, but you're allowing plenty of the oestrogen through the skin. 'The rules are very clear that if you give a very high dose of oestrogen and you don't give enough progesterone, however that happens, you're putting that woman at risk of womb cancer,' she said. Prof Mukherjee said there was currently a 'culture of putting women on very high doses of oestrogen', which can make the womb lining thicken. 'It's like having a lawn in a woman's womb. Oestrogen makes the lawn grow. Progestogen cuts the lawn. But if it's not being cut, it grows thicker, and then you can get abnormal cells and cancer.' Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. But she also stressed that the biggest risk factor for womb cancer was obesity - meaning that on the whole, weight loss jabs can cut the risk of disease. 'These drugs reduce the risk of cancer,' Prof Mukherjee said. 'But if they are prescribed to a woman who's on oestrogen through the skin, and she might already have womb thickening because she's living with obesity, and she's not absorbing the progesterone because she's been put on a weight-loss injection, she's potentially getting loads of oestrogen on top of her thickened womb lining, and that could potentially unmask cancers that are there or drive an early cancer to a more advanced stage.' The BMS put together the guidelines after calls from GPs for advice to give to patients. Dr Janet Barter, the president of the Faculty of Sexual and Reproductive Healthcare, told The Telegraph that weight loss jabs can cause side effects such as "vomiting and severe diarrhoea in some patients'. 'Obviously this could render any medication, such as HRT tablets or oral contraception, ineffective if there hasn't been enough time for them to be fully absorbed,' she said. 'If these side-effects are occurring, then people should discuss the matter with their doctor or specialist clinician to find the combination of drugs that's right for them.' Sun Health has contacted Novo Nordisk and Eli Lilly - the makers of Wegovy and Mounjaro - for comment. It follows warnings from the Medicines and Healthcare products Agency (MHRA) that GLP-1 weight loss drugs could reduce the absorption of contraceptives, due to the fact they slow down the emptying of the stomach. The watchdog also said the jabs should not be used during pregnancy, while trying to conceive or breastfeeding, over fears they could lead to miscarriage or birth defects. The MHRA explained: 'This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby.' Dr Bassel Wattar, a consultant gynaecologist and medical director of clinical trials at Anglia Ruskin University, told The Sun: 'It's not the medication itself, but the weight loss that helps regulate a woman's hormones allowing her ovaries to function properly again. 'Pregnancy is more of a happy side effect.'
The Sun
27 minutes ago
- The Sun
New fat jabs warning over ‘increased risk of cancer – as experts fear they ‘stop common medication working'
WEIGHT loss jabs could prevent a medication taken by millions of women from working - and increase patients' risk of cancer. The British Menopause Society said the jabs could cause hormone imbalance in women taking hormone replacement therapy (HRT), particularly for those with obesity, putting them 'at increased risk of womb cancer'. It follows warnings to women on weight loss medications to take effective contraception, as the jabs could render the pill less effective. That's because weight loss drugs Wegovy and Mounjaro - as well as diabetes jab Ozempic - can delay the absorption of pills taken orally, as well slowing down the passage of food through the gut. Guidance suggests women taking HRT in pill form may also be at risk. The British Menopause Society (BMS) told doctors to closely monitor menopausal women on HRT who are also using weight-loss jabs. The treatment tops up the hormones oestrogen and progesterone, which dip to low levels as the menopause approaches. Data from 2023-24 showed that 2.6 million women in England rely on the drugs to alleviate hot flushes, night sweats, difficulty sleeping and mood changes. "During the last two years, since semaglutide and tirzepatide [the active ingredients in Wegovy and Mounjaro] received licenses for weight loss, there has been an increase in uptake of these medications through private clinics, while NHS prescribing is limited to specialist weight management services," the BMS guidance stated. "There are no current data available about numbers of women receiving HRT concurrently with semaglutide or tirzepatide." The most common form of HRT is a progesterone pill alongside a skin patch or gel to deliver oestrogen, but some people opt for a combined pill. Progesterone balances out the effects of oestrogen, which on its own stimulates the growth of the womb lining, and can cause 'abnormal cells and cancer' to grow. Women taking fat jabs need 'effective contraception' - as health chiefs warn of serious harm to unborn babies The menopause experts expressed concern over the loss of the progesterone's protective effect on the womb as a result of weight loss jabs. They recommended that doctors move women taking progesterone orally to an intrauterine device, such as a Mirena coil, or increase their dose of progesterone. Prof Annice Mukherjee, a consultant endocrinologist and member of the society's medical advisory council, who led on the guidance, told The Telegraph that a hormone imbalance could put women 'at increased risk of womb cancer' - particularly if they are obese. 'Oestrogen is almost always given through the skin for HRT in women living with obesity, but progesterone is frequently given as a tablet, and that formulation is thought to be the safest route for women who have complicated health issues,' she said. 'If we then start one of these injectable weight-loss drugs, then you're preferentially stopping absorption of the progestogen that's coming in orally, but you're allowing plenty of the oestrogen through the skin. 'The rules are very clear that if you give a very high dose of oestrogen and you don't give enough progesterone, however that happens, you're putting that woman at risk of womb cancer,' she said. Prof Mukherjee said there was currently a 'culture of putting women on very high doses of oestrogen', which can make the womb lining thicken. 'It's like having a lawn in a woman's womb. Oestrogen makes the lawn grow. Progestogen cuts the lawn. But if it's not being cut, it grows thicker, and then you can get abnormal cells and cancer.' Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. But she also stressed that the biggest risk factor for womb cancer was obesity - meaning that on the whole, weight loss jabs can cut the risk of disease. 'These drugs reduce the risk of cancer,' Prof Mukherjee said. 'But if they are prescribed to a woman who's on oestrogen through the skin, and she might already have womb thickening because she's living with obesity, and she's not absorbing the progesterone because she's been put on a weight-loss injection, she's potentially getting loads of oestrogen on top of her thickened womb lining, and that could potentially unmask cancers that are there or drive an early cancer to a more advanced stage.' The BMS put together the guidelines after calls from GPs for advice to give to patients. Dr Janet Barter, the president of the Faculty of Sexual and Reproductive Healthcare, told The Telegraph that weight loss jabs can cause side effects such as "vomiting and severe diarrhoea in some patients'. 'Obviously this could render any medication, such as HRT tablets or oral contraception, ineffective if there hasn't been enough time for them to be fully absorbed,' she said. 'If these side-effects are occurring, then people should discuss the matter with their doctor or specialist clinician to find the combination of drugs that's right for them.' Sun Health has contacted Novo Nordisk and Eli Lilly - the makers of Wegovy and Mounjaro - for comment. It follows warnings from the Medicines and Healthcare products Agency (MHRA) that GLP-1 weight loss drugs could reduce the absorption of contraceptives, due to the fact they slow down the emptying of the stomach. The watchdog also said the jabs should not be used during pregnancy, while trying to conceive or breastfeeding, over fears they could lead to miscarriage or birth defects. medicine could cause harm to the baby.' Dr Bassel Wattar, a consultant gynaecologist and medical director of clinical trials at Anglia Ruskin University, told The Sun: 'It's not the medication itself, but the weight loss that helps regulate a woman's hormones allowing her ovaries to function properly again. 'Pregnancy is more of a happy side effect.'
